CA2397256A1 - Combinaisons de farnesyl-proteine transferase avec des derives de podophyllotoxine anti-tumoraux - Google Patents

Combinaisons de farnesyl-proteine transferase avec des derives de podophyllotoxine anti-tumoraux Download PDF

Info

Publication number
CA2397256A1
CA2397256A1 CA002397256A CA2397256A CA2397256A1 CA 2397256 A1 CA2397256 A1 CA 2397256A1 CA 002397256 A CA002397256 A CA 002397256A CA 2397256 A CA2397256 A CA 2397256A CA 2397256 A1 CA2397256 A1 CA 2397256A1
Authority
CA
Canada
Prior art keywords
6alkyl
hydrogen
6alkyloxy
formula
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002397256A
Other languages
English (en)
Inventor
Mary Ellen Margaret Rybak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2397256A1 publication Critical patent/CA2397256A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des combinaisons d'un inhibiteur de farnésyl transférase avec un dérivé de podophyllotoxine anti-tumoral destinées à inhiber la croissance des cellules tumorales et utiles dans le traitement du cancer.
CA002397256A 2000-02-29 2001-02-26 Combinaisons de farnesyl-proteine transferase avec des derives de podophyllotoxine anti-tumoraux Abandoned CA2397256A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200695 2000-02-29
EP00200695.5 2000-02-29
PCT/EP2001/002167 WO2001064198A2 (fr) 2000-02-29 2001-02-26 Combinaisons de farnesyl-proteine transferase avec des derives de podophyllotoxine anti-tumoraux

Publications (1)

Publication Number Publication Date
CA2397256A1 true CA2397256A1 (fr) 2001-09-07

Family

ID=8171114

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002397256A Abandoned CA2397256A1 (fr) 2000-02-29 2001-02-26 Combinaisons de farnesyl-proteine transferase avec des derives de podophyllotoxine anti-tumoraux

Country Status (5)

Country Link
EP (1) EP1267871A2 (fr)
JP (1) JP2003525238A (fr)
AU (1) AU2001239275A1 (fr)
CA (1) CA2397256A1 (fr)
WO (1) WO2001064198A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4820758B2 (ja) 2004-09-22 2011-11-24 日本化薬株式会社 新規ブロック共重合体、ミセル調製物及びそれを有効成分とする抗癌剤
CA2634598A1 (fr) 2005-12-23 2007-07-05 Link Medicine Corporation Traitement de formes de synucleinopathie
US8323669B2 (en) 2006-03-28 2012-12-04 Nippon Kayaku Kabushiki Kaisha Polymer conjugate of taxane
RU2447095C2 (ru) * 2006-05-18 2012-04-10 Ниппон Каяку Кабусики Кайся Высокомолекулярный конъюгат подофиллотоксинов
US8334364B2 (en) 2006-11-06 2012-12-18 Nipon Kayaku Kabushiki Kaisha High-molecular weight derivative of nucleic acid antimetabolite
JP5548365B2 (ja) 2006-11-08 2014-07-16 日本化薬株式会社 核酸系代謝拮抗剤の高分子誘導体
JP5349318B2 (ja) 2007-09-28 2013-11-20 日本化薬株式会社 ステロイド類の高分子結合体
CN101977631A (zh) 2008-03-18 2011-02-16 日本化药株式会社 生理活性物质的高分子量偶联物
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
JP5544357B2 (ja) 2009-05-15 2014-07-09 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
KR20140024833A (ko) 2010-11-17 2014-03-03 니폰 가야꾸 가부시끼가이샤 신규한 시티딘계 대사길항제의 고분자 유도체
CN103874722B (zh) 2011-09-11 2016-06-29 日本化药株式会社 嵌段共聚物的制造方法
CN105073729A (zh) 2012-10-16 2015-11-18 詹森药业有限公司 RORγt的苯基连接的喹啉基调节剂
US9290476B2 (en) 2012-10-16 2016-03-22 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
CN104884448A (zh) 2012-10-16 2015-09-02 詹森药业有限公司 Rorγt的杂芳基连接的喹啉基调节剂
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
BR112016008258A2 (pt) 2013-10-15 2017-10-10 Janssen Pharmaceutica Nv moduladores de ror?t de quinolinila
BR112016008215A2 (pt) 2013-10-15 2017-09-26 Janssen Pharmaceutica Nv moduladores de quinolinila ligados por alquila de roryt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
SK283335B6 (sk) * 1995-12-08 2003-06-03 Janssen Pharmaceutica N. V. (Imidazol-5-yl)metyl-2-chinolinónové deriváty, spôsob a medziprodukty na ich prípravu, ich použitie a farmaceutické kompozície na ich báze
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
RU2205831C2 (ru) * 1997-04-25 2003-06-10 Янссен Фармацевтика Н.В. Хиназолиноны, ингибирующие фарнезилтрансферазу
DK1041985T3 (da) * 1997-12-22 2006-06-19 Schering Corp Kombination af benzocycloheptapyridinforbindelser og antineoplastiske lægemidler til behandling af profilerative sygdomme
AU4562799A (en) * 1998-06-15 2000-01-05 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
JP2002519376A (ja) * 1998-07-02 2002-07-02 メルク エンド カムパニー インコーポレーテッド プレニル蛋白トランスフェラーゼ阻害薬
ID29241A (id) * 1998-12-23 2001-08-16 Janssen Pharmaceutica Nv Turunan-turunan kinolin teranelasi-1,2

Also Published As

Publication number Publication date
WO2001064198A2 (fr) 2001-09-07
WO2001064198A3 (fr) 2002-03-21
EP1267871A2 (fr) 2003-01-02
AU2001239275A1 (en) 2001-09-12
JP2003525238A (ja) 2003-08-26

Similar Documents

Publication Publication Date Title
CA2397349A1 (fr) Inhibiteur de farnesyl proteine transferase associe a un anticorps her2
CA2397657A1 (fr) Combinaisons d'inhibiteur de farnesyl proteine transferase et de composes de platine
CA2397256A1 (fr) Combinaisons de farnesyl-proteine transferase avec des derives de podophyllotoxine anti-tumoraux
CA2397240A1 (fr) Inhibiteur de farnesyl proteine transferase associe a des composes de camptothecine
CA2396865C (fr) Inhibiteurs de la farnesyl proteine transferase pour le traitement du cancer du sein
CA2397446A1 (fr) Combinaisons d'inhibiteur de farnesyl proteine transferase et d'agents d'alkylation antitumoraux
CA2397558A1 (fr) Regime posologique
CA2397694A1 (fr) Combinaisons d'inhibiteur de farnesyl-proteine transferase
CA2397690A1 (fr) Inhibiteur de farnesyl proteine transferase associe a des derives nucleosidiques anti-cancereux
CA2397425A1 (fr) Combinaisons d'inhibiteur de farnesyl-proteine transferase avec compose a base de taxane
CA2397448A1 (fr) Inhibiteur de farnesyl proteine transferase associe a d'autres agents anti-cancereux
CA2397253A1 (fr) Combinaisons d'inhibiteurs de farnesyl proteine transferase et de derives antitumoraux d'anthracycline
US20030050323A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor podophyllotoxin derivatives
US20030060480A1 (en) Farnesyl protein transferase inhibitor combinations with vinca alkaloids
CA2397475A1 (fr) Combinaisons d'inhibiteurs de farnesyl proteine transferase et de vinca-alcaloides
US20030125268A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor anthracycline derivatives

Legal Events

Date Code Title Description
FZDE Dead